

Full Length Research Paper

Prevalence and characterization of extended-spectrum beta-lactamase production in clinical isolates of *Klebsiella* spp.

Rashid Ramazanzadeh

Microbiology Department, Faculty of Medicine, Kurdistan University of Medical Science, Sanandaj, Iran.
E-mail: rashid@muk.ac.ir or atrop_t51@yahoo.com.

Accepted 20 January, 2017

Extended-spectrum beta-lactamases (ESBLs) are most prevalent in *Klebsiella pneumoniae*. This organism is frequently isolated from clinical specimens and can cause septicemia, pneumonia or urinary tract infection. We investigated a spread of *Klebsiella* spp. isolates producing ESBL in a university hospital of Sanandaj- Iran. Over one year period, a total of 48 *K. pneumoniae* isolates, were examined by double disk tests and PCR methods. Ten isolates were defined as ESBLs. The ESBL producer isolates was more resistant to selected antibiotics than ESBL negative isolates. The most frequent ESBL type was CTX-M. This is the first report of *Klebsiella* spp. isolates producing ESBL in Sanandaj hospitals. Production of ESBLs by *K. pneumoniae* is a widespread nosocomial problem. Knowledge about their prevalence is essential to guide towards appropriate infection control and antibiotic management strategies.

Key words: Extended-spectrum -lactamase (ESBL), hospital, *Klebsiella* spp.

INTRODUCTION

Multidrug resistant gram negative bacilli belonging to the family Enterobacteriaceae have been increasingly responsible for infections among the neonates admitted to the hospitals in many countries and *Klebsiella* spp. Constitutes a majority of these pathogens (Baby et al., 2008; Liu et al., 2008; Usha et al., 2008; Vinue et al., 2008). Resistance of *Klebsiella pneumoniae* to extended-spectrum -lactams antibiotics is commonly mediated by -lactamases. Indeed, *K. pneumoniae* is a major host of plasmid-located extended-spectrum beta-lactamases (ESBL). ESBLs are clavulanate-susceptible enzymes capable of hydrolyzing oxyimino-cephalosporins and monobactams, but not cephamycins and carbapenems. Infections due to ESBL-producing bacteria present a major therapeutic dilemma since the choice of antibiotics is restricted. Nosocomial outbreaks are often caused by ESBL-producing isolates, particularly in intensive care, they result from the clonally transmission of epidemic isolate and/or the horizontal transfer of resistance genes Messai et al. (2008).

Many and regular studies on ESBL- producing bacteria are conducted in numerous countries, whereas very few

information on this issue is available in Iran. We performed this study in clinical isolates of *Klebsiella* spp., collected from two hospitals in Sanandaj, to investigate the prevalence of ESBLs.

MATERIALS AND METHODS

Study population and specimen types

This study was conducted at Faculty of Medicine, Kurdistan University of Medical science, Sanandaj, Iran. From January 2007 to January 2008, 48 consecutive, non-duplicate isolates of *Klebsiella* spp. were collected from various specimens (abscesses, blood, lung, trachea and urine) of patients who were referred to Toohid and Beesat Hospitals.

Microbiological methods

All samples were routinely cultured on MacConkey and blood agar plates. Blood samples were cultured in Blood culture bottles. Isolates were identified at the species level using standard biochemical tests and microbiological methods. Only one isolate per patient was included in the study.

Table 3. Antimicrobial Resistance Pattern of *Klebsiella* spp. Isolates (in percentage) from Sanadaj hospitals.

Isolates	A	Cf	Ct	Ci	G	An	Cp	Nor	Te	Na	Sxt
ESBL positive	80	90	90	90	70	40	60	60	33.33	11.11	70
ESBL negative	42.11	39.47	39.47	18.42	28.95	28.95	13.16	2.63	33.33	15.38	34.21

A- Ampicillin, Cf- Cefalotin, Ct- Ceftizoxim, Ci- Ceftriaxone, G- Gentamicin, An- Amikacin, Cp- Ciprofloxacin, Nor- Norfloxacin, Te- Tetracycline, Na- Nalidixic acid, Sxt- Trimethoprim sulfamethoxazole

Table 4. Distribution of extended spectrum beta-lactamase types in Sanandaj two general hospitals

ESBL type	Hospital		
	Besat H. (%)	Yo ohid H. (%)	Total (%)
CTX-M	12.50	8.33	20.83
SHV	10.42	8.33	18.75
TEM	8.33	6.25	14.85
OXA-1	10.42	4.17	14.58
OXA-2	0.00	4.17	4.17

practice in our country.

Most of ESBL-positive *Klebsiella* spp. has been isolated from urinary tract infection and blood stream infection (6.25%). Therefore, the high rate of ESBL-positive isolate with this infection might be determining the nosocomial spread of this enzyme.

We found ciprofloxacin resistance in 60% in ESBL positive and 13.16% in ESBL negative of *Klebsiella* bacteria. There were marked geographic differences in the occurrence of ciprofloxacin resistance, resistance rates were in range of 33 to 60% of ESBL producing isolates. Ciprofloxacin resistance in *K. pneumoniae* is closely associated with ESBLs. This association is of grave concern since ESBL-producing isolates are usually resistant to penicillins, cephalosporins, aminoglycosides and TMP-SMZ. Therefore, ciprofloxacin resistance severely limits already restricted treatment Paterson et al. (2000); Paterson et al. (2004).

CTX-M type ESBLs have become widely dispersed in many parts of the world and these enzymes confer higher levels of resistance to cefotaxime than to ceftazidime Bonnet (2004). The prevalence of *bla*_{CTX-M} was 20.83% for ESBL-producing *Klebsiella* strains. ESBL-producing bacteria carried *bla*_{SHV} at 18.75%. In comparison with Thailand studies Kiratisin et al. (2008), the rate of *bla*_{CTX-M} and *bla*_{SHV} were very low. In Indian studies Baby et al. (2008) also, the majority of isolates (19/23) belonged to CTX-M type ESBLs and one isolate was positive for both CTX-M and SHV gene. SHV-type and CTX-M ESBLs have appeared in many Canadian isolates Bush (2008). TEM gene was detected in 41 (65.1%) and 19 (46.3%), whereas SHV gene in 18 (28.6%) and 20 (48.8%) of *E. coli* and *K. pneumoniae* strains, respectively. SHV enzymes are common plasmid-mediated -lactamase, which are chromosomally encoded in the majority of

isolates of *K. pneumoniae* Arlet et al. (1999), Mahrouki et al. (2008), Messai et al. (2008) and Vinue et al. (2008). *Bla* genes encoding TEM, OXA-1 and OXA-2 were found in ESBL-producing strains 14.85, 14.58 and 4.17%, respectively. TEM gene was detected in 41 (65.1%) and 19 (46.3%), whereas SHV gene was 18 (28.6%) and 20 (48.8%) in *E. coli* and *K. pneumoniae* strains, respectively. TEM was originally isolated from blood culture of a patient named Temoniera in Greece, in the early 1960s. TEM being plasmid and transposon mediated has facilitated its spread to other species of bacteria Bradford (2001); Baby et al. (2008); Usha et al. (2008); Vinue et al. (2008). As reported from most part of the world, quite marked differences have since been seen in the pattern of ESBL genes. ESBL production rates are now very high compared with Europe Hawkey (2008) and USA Canton et al. (2008). However, spread of mobile genetic elements, mainly epidemic plasmids and the dispersion of specific clones have been responsible for the increase in ESBL-producing isolates.

In conclusion, this study documents the presence of beta-lactamase among *Klebsiella* isolates in two Sanandaj general hospitals. The prevalence of ESBL producers at our study was lower in comparison to the prevalence reported from other studies. Routine detection of ESBL-producing microorganisms is required to be done by each laboratory by the standard detection methods so as to control the spread of these infections and also to institute proper therapeutic strategies.

ACKNOWLEDGEMENTS

The author wish to extend his gratitude to the Research Deputy of Kurdistan University of Medical science for financial support and also thank Microbiology Laboratory staff of the Beesat and Toohid Hospitals, for technical support.

REFERENCES

- Arlet G, Goussard S, Courvalin Philippon A (1999). Sequences of the genes for the TEM-20, TEM-21, TEM-22, and TEM-29 extended-spectrum beta-lactamases. *Antimicrob. Agents Chemother.* 43: 969-71.
- Baby Padmini S, Appala Raju Bmani KR (2008). Detection of Enterobacteriaceae producing CTX-M extended spectrum beta-lactamases from a tertiary care hospital in south India. *Indian J. Med. Microbiol.* 26: 163-6.
- Bonnet R (2004). Growing group of extended - spectrum beta lactamas-

- es: the CTX-M enzymes. *Antimicrob. Agents Chemother.* 48: 1-14.
- Bradford PA (2001). Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. *Clin. Microbiol. Rev.* 14: 933-51.
- Bush K (2008). Extended-spectrum beta-lactamases in North America, 1987-2006. *Clin. Microbiol. Infect.* 14(1): 134-43.
- Canton R, Novais A, Valverde A, Machado E, Peixe L, Baquero FCoque TM (2008). Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe. *Clin. Microbiol. Infect.* 14(1): 144-53.
- Clinical and laboratory standards institute C (2009). Performance standards for antimicrobial susceptibility testing.
- Demir S, Soysal A, Bakir M, Kaufmann M EYagci A (2008). Extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* in paediatric wards: A nested case-control study. *J. Paediatr. Child Health.*
- Feizabadi MM, Etemadi G, Yadegarinia D, Rahmati M, Shabanpoor SBokaei S (2006). Antibiotic-resistance patterns and frequency of extended-spectrum beta-lactamase-producing isolates of *Klebsiella pneumoniae* in Tehran. *Med. Sci. Monit.* 12: 362-365.
- Hawkey PM (2008). Prevalence and clonality of extended-spectrum beta-lactamases in Asia. *Clin. Microbiol. Infect.* 14(1): 159-65.
- Jarlier V, Nicolas MH, Fournier G, Philippon A (1988). Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. *Rev. Infect. Dis.* 10: 867-78.
- Kiratisin P, Apisarnthanarak A, Laesripa C Saifon P (2008). Molecular Characterization and Epidemiology of Extended-Spectrum- (beta)-Lactamase-Producing *Escherichia coli* and *Klebsiella pneumoniae* Isolates Causing Health Care-Associated Infection in Thailand, Where the CTX-M Family Is Endemic. *Antimicrob. Agents Chemother.* 52: 2818-2824.
- KoreaKo CS, Sung JY, Koo SH, Kwon GC, Shin SY, Park JW (2007). [Prevalence of extended-spectrum beta-lactamases in *Escherichia coli* and *Klebsiella pneumoniae* from Daejeon]. *Korean J. Lab. Med.* 27: 344-50.
- Liu G, Ling BD, Zeng Y, Lin L, Xie Y, ELei J (2008). Molecular Characterization of Extended-Spectrum Beta-Lactamases Produced by Clinical Isolates of *Enterobacter cloacae* from a Teaching Hospital in China. *Jpn. J. Infect. Dis.* 61: 286-289.
- Mahrouki S, Ben-Achour N, Chouchani C, Ben-Moussa M Belhadj O (2008). Identification of plasmid-encoded extended spectrum beta-lactamases produced by a clinical strain of *Proteus mirabilis*. *Pathol. Biol.* 57: 55-59.
- Messai Y, Iabadene H, Benhassine T, Alouache S, Tazir M, Gautier V, Arlet GBakour R (2008). Prevalence and characterization of extended-spectrum [beta]-lactamases in *Klebsiella pneumoniae* in Algiers hospitals (Algeria). *Pathol. Biol.* 56: 319-325.
- Messai Y, Iabadene H, Benhassine T, Alouache S, Tazir M, Gautier V, Arlet GBakour R (2008). Prevalence and characterization of extended-spectrum beta-lactamases in *Klebsiella pneumoniae* in Algiers hospitals (Algeria). *Pathol. Biol.* 56: 319-25.
- Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, Mulazimoglu L, Trenholme G, Klugman KP, Bonomo RA, Rice LB, Wagener MM, McCormack J, GYu VL (2004). International prospective study of *Klebsiella pneumoniae* bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial infections. *Ann. Int. Med.* 140: 26-32.
- Paterson DL, Mulazimoglu L, Casellas JM, Ko WC, Goossens H, Von Gottberg A, Mohapatra S, Trenholme GM, Klugman KP, McCormack J, GYu VL (2000). Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in *Klebsiella pneumoniae* isolates causing bacteremia. *Clin. Infect. Dis.* 30: 473-8.
- Shahcheraghi F, Moezi H Feizabadi MM (2007). Distribution of TEM and SHV beta-lactamase genes among *Klebsiella pneumoniae* strains isolated from patients in Tehran. *Med. Sci. Monit.* 13: 247-250.
- Spanu T, Luzzaro F, Perilli M, Amicosante G, Toniolo AFadda G (2002). Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs. *Antimicrob. Agents Chemother.* 46: 196-202.
- Usha G, Chunderika M, Prashini M, Willem SA, Yusuf ES (2008). Characterization of extended-spectrum beta-lactamases in *Salmonella* spp. at a tertiary hospital in Durban, South Africa. *Diagn. Microbiol. Infect. Dis.* 62: 86-91.
- Vinue L, Lantero M, Saenz Y, Somalo S, de Diego I, Perez F, Ruiz-Larrea F, Zarazaga MTorres C (2008). Characterization of extended-spectrum beta-lactamases and integrons in *Escherichia coli* isolates in a Spanish hospital. *J. Med. Microbiol.* 57: 916-20.
- Yao F, Qian Y, Chen S, Wang PHuang Y (2007). Incidence of Extended-Spectrum beta-Lactamases and Characterization of Integrons in Extended-Spectrum beta-Lactamase-producing *Klebsiella pneumoniae* Isolated in Shantou, China. *Acta. Biochim. Biophys. Sin. (Shanghai).* 39: 527-32.